Endonovo's SofPulse® Secures Taiwan FDA Approval
The SofPulse® TFDA approval marks the initial phase of Endonovo's expansion, through EverMed, into the largely untapped PEMF and surgical sectors in Taiwan.
- The SofPulse® TFDA approval marks the initial phase of Endonovo's expansion, through EverMed, into the largely untapped PEMF and surgical sectors in Taiwan.
- Ira Weisberg, President of Endonovo's SofPulse® division, stated: "We are eager to collaborate with EverMed to expand SofPulse® use throughout Taiwan.
- The TFDA is the regulatory arm of Taiwan’s MOHW and is considered the driving force behind healthcare improvement in Taiwan.
- The establishment of an international distribution agreement in Taiwan, with EverMed helps establish Endonovo’s willingness to expand globally into new regions increasing brand awareness internationally.